Steffen Christensen

Steffen Christensen

Auto-generated profile, based on publicly available information

Steffen Christensen

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2011 in BMC Medical Research Methodology
Verified
Journal Article
Open access
PDF file
STSandra K Thygesen
Sandra K Thygesen
CCChristian F Christiansen
Christian F Christiansen
SCSteffen Christensen
Steffen Christensen
TLTimothy L Lash
Timothy L Lash
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
The Charlson comorbidity index is often used to control for confounding in research based on medical databases. There are few studies of the accuracy of the codes obtained from these databases.

1 June 2011 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
SCSteffen Christensen
Steffen Christensen
MJMartin Johansen
Martin Johansen
CCChristian Fynbo Christiansen
Christian Fynbo Christiansen
RJReinhold Jensen
Reinhold Jensen
SLStanley Lemeshow
Stanley Lemeshow
Background: Physiology-based severity of illness scores are often used for risk adjustment in observational studies of intensive care unit (ICU) outcome. However, the complexity and time constraints of these scoring systems may limit their use in administrative databases. Comorbidity is a main determinant of ICU outcome, and comorbidity scores can be computed based on data from most administrative databases. However, limited data exist on the performance of comorbidity scores in predicting mortality of ICU patients. Objectives: To examine the performance of the Charlson comorbidity index (CCI) alone and in combination with other readily available administrative data and three physiology-based scores (acute physiology and chronic health evaluations [APACHE] II, simplified acute physiology score [SAPS] II, and SAPS III) in predicting short- and long-term mortality following intensive care. Methods: For all adult patients (n = 469) admitted to a tertiary university–affiliated ICU in 2007, we computed APACHE II, SAPS II, and SAPS III scores based on data from medical records. Data on CCI score age and gender, surgical/medical status, social factors, mechanical ventilation and renal replacement therapy, primary diagnosis, and complete follow-up for 1-year mortality was obtained from administrative databases. We computed goodness-of-fit statistics and c-statistics (area under ROC [receiver operating characteristic] curve) as measures of model calibration (ability to predict mortality proportions over classes of risk) and discrimination (ability to discriminate among the patients who will die or survive), respectively. Results: Goodness-of-fit statistics supported model fit for in-hospital, 30-day, and 1-year mortality of all combinations of the CCI score. Combining the CCI score with other administrative data revealed c-statistics of 0.75 (95% confidence interval [CI] 0.69–0.81) for in-hospital mortality, 0.75 (95% CI 0.70–0.80) for 30-day mortality, and 0.72 (95% CI 0.68–0.77) for 1-year mortality. There were no major differences in c-statistics between physiology-based systems and the CCI combined with other administrative data. Conclusion: The CCI combined with administrative data predict short- and long-term mortality for ICU patients as well as physiology-based scores.

4 November 2008 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
JKJette B Kornum
Jette B Kornum
SCSteffen Christensen
Steffen Christensen
MGMiriam Grijota
Miriam Grijota
LPLars Pedersen
Lars Pedersen
PWPia Wogelius
Pia Wogelius
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
Background: Current data on incidence of interstitial lung diseases (ILDs) are sparse and concerns about an increasing trend have been raised. We examined incidence rates (IRs) of ILDs and changes in IRs between 1995 and 2005.Methods: All persons with a first-time hospital discharge or outpatient diagnosis of ILD were identified through the Danish National Registry of Patients, which covers all Danish hospitals. Crude and age-standardised IRs were computed for ILD overall, as well as stratified by ILD subcategories.Results: A total of 21,765 patients with ILD were identified. Between 1995 and 1998 the overall standardised IR of ILD decreased from 27.14 (95% CI 25.82–28.46) per 100,000 person-years to 19.36 (95% CI 18.26–20.46) per 100,000 person-years. After 1998 the IR increased considerably, peaking at 34.34 (95% CI 32.84–35.85) per 100,000 person-years in 2002. Subsequently there was a slight decrease. The highest IR was observed in the non-specific category "Respiratory disorders in diseases classified elsewhere". By ILD subcategory, the greatest average increase during the study period was observed in "Respiratory disorders in diseases classified elsewhere".Conclusion: The incidence rate of ILD in Denmark increased during the study period, most pronounced for ILDs associated with systemic diseases.

17 April 2007 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
SCSteffen Christensen
Steffen Christensen
ARAnders Riis
Anders Riis
MNMette Nørgaard
Mette Nørgaard
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
RTReimar W Thomsen
Reimar W Thomsen
Mortality after perforated and bleeding peptic ulcer increases with age. Limited data exist on how the higher burden of comorbidity among elderly patients affects this association. We aimed to examine the association of age with short-term mortality after perforated and bleeding peptic ulcer and to determine the impact of comorbidity on this association. In this population-based cohort study in three Danish counties between 1991 and 2003 we identified two cohorts of patients: those hospitalized with a first-time discharge diagnosis of perforated peptic ulcer and those with bleeding peptic ulcer. The diagnoses were ascertained from hospital discharge registries and mortality through the Danish Civil Registration System. Information on comorbidity and use of ulcer-related drugs was obtained through administrative medical databases. We computed age-, gender- and comorbidity-standardized 30-day mortality rates and used Cox's regression to estimate adjusted 30-day mortality rate ratios (MRR) for elderly compared with younger patients. Among 2,061 patients with perforated peptic ulcer, 743 (36%) were 65–79 years old and 513 patients (25%) were aged 80+ years. Standardized 30-day mortality was 8.9% among patients younger than 65 years rising to 44.6% among patients aged 80+ years, corresponding to an adjusted MRR of 5.3 (95% CI: 4.0–7.0). Among 7,232 patients with bleeding peptic ulcer 2,372 (33%) were aged 80+ years. Standardized 30-day mortality among patients younger than 65 was 4.3% compared with 16.9% among patients aged 80+ years, corresponding to an adjusted MRR of 3.7 (95% CI: 2.9–4.7). Analyses stratified by comorbidity consistently showed high MRRs among elderly patients, regardless of comorbidity level. Ageing is a strong predictor for a poor outcome after perforated and bleeding peptic ulcer independently of comorbidity.

9 September 2013 in Critical Care
Verified
Journal Article
Open access
PDF file
CCChristian Fynbo Christiansen
Christian Fynbo Christiansen
MJMartin Johansen
Martin Johansen
SCSteffen Christensen
Steffen Christensen
JOJames M O’brien
James M O’brien
ETElse Tønnesen
Else Tønnesen
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
Introduction: Metformin has anti-inflammatory and anti-thrombotic effects that may improve the outcome of critical illness, but clinical data are limited. We examined the impact of preadmission metformin use on mortality among intensive care unit (ICU) patients with type 2 diabetes. Methods: We conducted this population-based cohort study among all persons admitted to the 17 ICUs in Northern Denmark (population approximately 1.8 million). We focused on all patients with type 2 diabetes who were admitted to the ICUs between January 2005 and December 2011. Through individual-level linkage of population-based medical databases, type 2 diabetes was identified using a previously validated algorithm including hospital diagnoses, filled prescriptions for anti-diabetic drugs, and elevated HbA1c levels. Metformin use was identified by filled prescriptions within 90 days before admission. Covariates included surgery, preadmission morbidity, diabetes duration, and concurrent drug use. We computed 30-day mortality and hazard ratios (HRs) of death using Cox regression adjusted for covariates, both overall and after propensity score matching. Results: We included 7,404 adult type 2 diabetes patients, representing 14.0% of 52,964 adult patients admitted to the ICUs. Among type 2 diabetes patients, 1,073 (14.5%) filled a prescription for metformin as monotherapy within 90 days before admission and 1,335 (18.0%) received metformin in combination with other anti-diabetic drugs. Thirty-day mortality was 17.6% among metformin monotherapy users, 17.9% among metformin combination therapy users, and 25.0% among metformin non-users. The adjusted HRs were 0.80 (95% confidence interval (CI): 0.69, 0.94) for metformin monotherapy users and 0.83 (95% CI: 0.71, 0.95) for metformin combination therapy users, compared to non-users. Propensity-score-matched analyses yielded the same results. The association was evident across most subgroups of medical and surgical ICU patients, but most pronounced in elderly patients and in patients with well-controlled diabetes. Former metformin use was not associated with decreased mortality. Conclusions: Preadmission metformin use was associated with reduced 30-day mortality among medical and surgical intensive care patients with type 2 diabetes.

7 March 2011 in Critical Care
Verified
Journal Article
Open access
PDF file
SCSteffen Christensen
Steffen Christensen
MJMartin Johansen
Martin Johansen
ETElse Tønnesen
Else Tønnesen
ALAnders Larsson
Anders Larsson
LPLars Pedersen
Lars Pedersen
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
Introduction: Beta-blockers have cardioprotective, metabolic and immunomodulating effects that may be beneficial to patients in intensive care. We examined the association between preadmission beta-blocker use and 30-day mortality following intensive care. Methods: We identified 8,087 patients over age 45 admitted to one of three multidisciplinary intensive care units (ICUs) between 1999 and 2005. Data on the use of beta-blockers and medications, diagnosis, comorbidities, surgery, markers of socioeconomic status, laboratory tests upon ICU admission, and complete follow-up for mortality were obtained from medical databases. We computed probability of death within 30 days following ICU admission for beta-blocker users and non-users, and the odds ratio (OR) of death as a measure of relative risk using conditional logistic regression and also did a propensity score-matched analysis. Results: Inclusion of all 8,087 ICU patients in a logistic regression analysis yielded an adjusted OR of 0.82 (95% confidence interval (CI): 0.71 to 0.94) for beta-blocker users compared with non-users. In the propensity score-matched analysis we matched all 1,556 beta-blocker users (19.2% of the entire cohort) with 1,556 non-users; the 30-day mortality was 25.7% among beta-blocker users and 31.4% among non-users (OR 0.74 (95% CI: 0.63 to 0.87)]. The OR was 0.69 (95% CI: 0.54 to 0.88) for surgical ICU patients and 0.71 (95% CI: 0.51 to 0.98) for medical ICU patients. The OR was 0.99 (95% CI: 0.67 to 1.47) among users of non-selective beta-blockers, and 0.70 (95% CI: 0.58 to 0.83) among users of cardioselective beta-blockers. Conclusions: Preadmission beta-blocker use is associated with reduced mortality following ICU admission.